Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA
Therapeutic Advances in Respiratory Disease · 2026-05 · 20
DOI: 10.1177/17534666261451630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 28.05.2026. Verfasst von Wenxue Bai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, …. Hauptthemen laut MEDLINE: Birt-Hogg-Dube Syndrome, RNA, Messenger, Tumor Suppressor Proteins, Proto-Oncogene Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant disorder caused by folliculin ( FLCN ) gene mutations, with ethnically heterogeneous mutational spectra. Current management is primarily supportive and lacks curative therapies.
Objectives
This study aimed to characterize the clinical features and genetic variants in two distinct Chinese families with BHD syndrome and to preliminarily explore the feasibility of an mRNA-based protein replacement approach.
Design
A family-based prospective cohort study was conducted to identify FLCN mutations in two BHD families carrying rare FLCN variants enrolled in 2023.
Methods
Whole-exome sequencing (WES) identified candidate mutations in probands, which were validated by Sanger sequencing (p.W376R and p.Q44*). Structural/functional impacts of p.W376R were analyzed via bioinformatics and qPCR. HEK293T cells were transfected with empty vector, wild-type FLCN , or mutant plasmids (p.W376R and p.Q44*), followed by co-transfection with or without synthetic FLCN mRNA. FLCN expression and mTORC1 signaling were assessed.
Results
Affected members in both families predominantly presented with respiratory symptoms, lacking typical skin lesions and kidney tumors. WES identified the FLCN variants p.W376R (previously classified as a Variant of Uncertain Significance, VUS) and a novel nonsense mutation p.Q44*. Genotype–phenotype co-segregation was confirmed for p.W376R. In vitro analyses demonstrated that both mutations reduced FLCN protein expression, leading to mTORC1 hyperactivation. Exogenous FLCN mRNA delivery rescued functional protein expression and reversed mTORC1 dysregulation.
Conclusion
We provide co-segregation and functional evidence supporting the reclassification of the FLCN p.W376R variant as pathogenic according to ACMG guidelines and report a novel pathogenic mutation, p.Q44*, expanding the known FLCN mutational spectrum. Importantly, FLCN mRNA supplementation restored FLCN expression in vitro, providing preliminary evidence for mRNA-based therapeutic strategies in BHD syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang, China.
- Division of Cardiology, Departments of Internal Medicine and Genetic Diagnosis Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
ORCID-Profile: Mengyao Guo, Lirong Chen, Bingyi Liu, Min Xie
Zitieren
APA
Bai, W., Guo, M., Hua, L., Wang, X., Chen, L., Liu, B., Wang, Y., Zhou, Y., Wang, Q., Zhang, N., Chen, L., Wu, M., Li, Z., & Xie, M. (2026). Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261451630
Vancouver
Bai W, Guo M, Hua L, Wang X, Chen L, Liu B, et al. Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261451630
BibTeX
@article{Bai2026,
author = {Bai, Wenxue and Guo, Mengyao and Hua, Lijuan and Wang, Xuezhao and Chen, Lirong and Liu, Bingyi and Wang, Yi and Zhou, Ying and Wang, Qi and Zhang, Ni and Chen, Lan and Wu, Min and Li, Zongzhe and Xie, Min},
title = {Novel FLCN mutations in Birt-Hogg-Dubé patients and potential intervention of FLCN mRNA},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261451630}
}
EUVIMED